{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:25:40Z","timestamp":1791357940036,"version":"4.3.1"},"reference-count":32,"publisher":"Journal of Neurosurgery Publishing Group (JNSPG)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JNS"],"published-print":{"date-parts":[[2008,5]]},"abstract":"<jats:sec>\n                    <jats:title>Object<\/jats:title>\n                    <jats:p>\n                      The object of this study was to investigate the safety and clinical responses of immunotherapy targeting the\n                      <jats:italic>WT1<\/jats:italic>\n                      (Wilms tumor 1) gene product in patients with recurrent glioblastoma multiforme (GBM).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Twenty-one patients with WT1\/HLA-A*2402\u2013positive recurrent GBM were included in a Phase II clinical study of WT1 vaccine therapy. In all patients, the tumors were resistant to standard therapy. Patients received intra-dermal injections of an HLA-A*2402\u2013restricted, modified 9-mer WT1 peptide every week for 12 weeks. Tumor size, which was obtained by measuring the contrast-enhanced area on magnetic resonance images, was determined every 4 weeks. The responses were analyzed according to Response Evaluation Criteria in Solid Tumors (RECIST) 12 weeks after the initial vaccination. Patients who achieved an effective response continued to be vaccinated until tumor progression occurred. Progression-free survival and overall survival after initial WT1 treatment were estimated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The protocol was well tolerated; only local erythema occurred at the WT1 vaccine injection site. The clinical responses were as follows: partial response in 2 patients, stable disease in 10 patients, and progressive disease in 9 patients. No patient had a complete response. The overall response rate (cases with complete or partial response) was 9.5%, and the disease control rate (cases with complete or partial response as well as those in which disease was stable) was 57.1%. The median progression-free survival (PFS) period was 20.0 weeks, and the 6-month (26-week) PFS rate was 33.3%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although a small uncontrolled nonrandomized trial, this study showed that WT1 vaccine therapy for patients with WT1\/HLA-A*2402\u2013positive recurrent GBM was safe and produced a clinical response. Based on these results, further clinical studies of WT1 vaccine therapy in patients with malignant glioma are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3171\/jns\/2008\/108\/5\/0963","type":"journal-article","created":{"date-parts":[[2008,4,30]],"date-time":"2008-04-30T15:10:40Z","timestamp":1209568240000},"page":"963-971","source":"Crossref","is-referenced-by-count":169,"title":["Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme"],"prefix":"10.3171","volume":"108","author":[{"given":"Shuichi","family":"Izumoto","sequence":"first","affiliation":[{"name":"Departments of Neurosurgery,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Tsuboi","sequence":"additional","affiliation":[{"name":"Cancer Immunotherapy,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Oka","sequence":"additional","affiliation":[{"name":"Respiratory Medicine, Allergy, and Rheumatic Diseases,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Departments of Neurosurgery,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Hashiba","sequence":"additional","affiliation":[{"name":"Departments of Neurosurgery,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Kagawa","sequence":"additional","affiliation":[{"name":"Departments of Neurosurgery,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Departments of Neurosurgery,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiko","family":"Maruno","sequence":"additional","affiliation":[{"name":"Departments of Neurosurgery,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga A.","family":"Elisseeva","sequence":"additional","affiliation":[{"name":"Functional Diagnostic Science,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Shirakata","sequence":"additional","affiliation":[{"name":"Functional Diagnostic Science,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Cancer Immunotherapy,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Oji","sequence":"additional","affiliation":[{"name":"Functional Diagnostic Science,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumiyuki","family":"Nishida","sequence":"additional","affiliation":[{"name":"Functional Diagnostic Science,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Ohno","sequence":"additional","affiliation":[{"name":"Cancer Immunotherapy,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Kawase","sequence":"additional","affiliation":[{"name":"Respiratory Medicine, Allergy, and Rheumatic Diseases,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Hatazawa","sequence":"additional","affiliation":[{"name":"Nuclear Medicine and Tracer Kinetics, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ichi","family":"Nakatsuka","sequence":"additional","affiliation":[{"name":"Pathology, Osaka University Graduate School of Medicine, Osaka; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyuki","family":"Aozasa","sequence":"additional","affiliation":[{"name":"Pathology, Osaka University Graduate School of Medicine, Osaka; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Morita","sequence":"additional","affiliation":[{"name":"Medical Administration Course of Master's Degree Program, Nagoya University, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Medical Administration Course of Master's Degree Program, Nagoya University, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruo","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Functional Diagnostic Science,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Yoshimine","sequence":"additional","affiliation":[{"name":"Departments of Neurosurgery,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1754","reference":[{"key":"b1-1080963","series-title":"Cancer Immunol Immunother","first-page":"844","article-title":"Escape from immunotherapy: possible mechanisms that influence tumor regression\/progression","volume":"53","author":"Ahmad","year":"2004"},{"key":"b2-1080963","series-title":"Int J Cancer","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1002\/ijc.1536","article-title":"Induction of systemic CTL responses in melanoma patients by dendritic cell vaccination: cessation of CTL responses is associated with disease progression","volume":"94","author":"Andersen","year":"2001"},{"key":"b3-1080963","series-title":"Ann Oncol","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1023\/A:1008382516636","article-title":"Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse","volume":"12","author":"Brada","year":"2001"},{"key":"b4-1080963","series-title":"Neurology","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1212\/01.WNL.0000140495.33615.CA","article-title":"How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial","volume":"63","author":"Brandes","year":"2004"},{"key":"b5-1080963","series-title":"J Neuroimmunol","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/0165-5728(89)90127-6","article-title":"Immunology of central nervous system tumors","volume":"25","author":"de Micco","year":"1989"},{"key":"b6-1080963","series-title":"Cancer Res","doi-asserted-by":"publisher","first-page":"3294","DOI":"10.1158\/0008-5472.CAN-05-3773","article-title":"Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma","volume":"66","author":"Fecci","year":"2006"},{"key":"b7-1080963","series-title":"J Exp Med","first-page":"241","article-title":"High frequency of antitumor T cells in the blood of mela-noma patients before and after vaccination with tumor antigens","volume":"201","author":"Germeau","year":"2004"},{"key":"b8-1080963","series-title":"Neurol Med Chir (Tokyo)","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2176\/nmc.47.165","article-title":"Expression of WT1 protein and correlation with cellular proliferation in glial tumors","volume":"47","author":"Hashiba","year":"2007"},{"key":"b9-1080963","series-title":"Ann Oncol","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1023\/A:1008267312782","article-title":"Malignant glioma: Should chemotherapy be overthrown by experimental treatments?","volume":"9","author":"Hosli","year":"1998"},{"key":"b10-1080963","series-title":"Cancer Sci","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1111\/j.1349-7006.2006.00272.x","article-title":"Personalized peptide vaccines: a new therapeutic modality for cancer","volume":"97","author":"Itoh","year":"2006"},{"key":"b11-1080963","series-title":"Surg Neurol","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.surneu.2004.08.094","article-title":"Immunohistochemical detection of female sex hormone receptors in craniopharyngiomas: correlation with clinical and histologic features","volume":"63","author":"Izumoto","year":"2005"},{"key":"b12-1080963","series-title":"Cancer Sci","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/j.1349-7006.2006.00169.x","article-title":"Wilms' tumor gene WT1 17AA(-)\/KTS(-) isoform induces morphological changes and promotes cell migration and invasion in vitro","volume":"97","author":"Jomgeow","year":"2006"},{"key":"b13-1080963","series-title":"J Immunol","first-page":"6867","article-title":"Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens","volume":"163","author":"Kammula","year":"1999"},{"key":"b14-1080963","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"5060","DOI":"10.1200\/JCO.2006.07.1100","article-title":"Phase I study of adoptive T-cell therapy using antigen-specific CD8+T cells for the treatment of patients with metastatic melanoma","volume":"24","author":"Mackensen","year":"2006"},{"key":"b15-1080963","series-title":"Jpn J Clin Oncol","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1093\/jjco\/hyl005","article-title":"A phase I\/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data","volume":"36","author":"Morita","year":"2006"},{"key":"b16-1080963","series-title":"Cancer Immunol Immunother","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s00262-003-0498-0","article-title":"WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone","volume":"53","author":"Nakajima","year":"2004"},{"key":"b17-1080963","series-title":"Curr Cancer Drug Targets","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2174\/1568009023334088","article-title":"WT1 as a novel target antigen for cancer immunotherapy","volume":"2","author":"Oka","year":"2002"},{"key":"b18-1080963","series-title":"Curr Med Chem","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.2174\/092986706777935104","article-title":"Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers","volume":"13","author":"Oka","year":"2006"},{"key":"b19-1080963","series-title":"Proc Natl Acad Sci U S A","doi-asserted-by":"publisher","first-page":"13885","DOI":"10.1073\/pnas.0405884101","article-title":"Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression","volume":"101","author":"Oka","year":"2004"},{"key":"b20-1080963","series-title":"J Immunol","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.4049\/jimmunol.164.4.1873","article-title":"Cancer immunotherapy targeting Wilms' tumor gene WT1 product","volume":"164","author":"Oka","year":"2000"},{"key":"b21-1080963","series-title":"Cancer Immunol Immunother","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00262-003-0473-9","article-title":"Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination","volume":"53","author":"Romero","year":"2004"},{"key":"b22-1080963","series-title":"N Engl J Med","first-page":"987","article-title":"European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005"},{"key":"b23-1080963","series-title":"J Natl Cancer Inst","first-page":"205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2006"},{"key":"b24-1080963","series-title":"J Clin Immunol","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1023\/A:1006637529995","article-title":"Cytotoxic T-lymphocyte responses elicited to Wilms' tumor gene WT1 product by DNA vaccination","volume":"20","author":"Tsuboi","year":"2000"},{"key":"b25-1080963","series-title":"Leuk Res","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S0145-2126(99)00037-5","article-title":"Constitutive expression of the Wilms' tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulation factor (G-CSF)","volume":"23","author":"Tsuboi","year":"1999"},{"key":"b26-1080963","series-title":"Cancer Immunol Immunother","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1007\/s00262-002-0328-9","article-title":"Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues","volume":"51","author":"Tsuboi","year":"2002"},{"key":"b27-1080963","series-title":"Clin Cancer Res","doi-asserted-by":"publisher","first-page":"5316","DOI":"10.1158\/1078-0432.CCR-04-0497","article-title":"Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination","volume":"10","author":"Wheeler","year":"2004"},{"key":"b28-1080963","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1200\/JCO.1999.17.8.2572","article-title":"Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials","volume":"17","author":"Wong","year":"1999"},{"key":"b29-1080963","series-title":"Clin Cancer Res","doi-asserted-by":"publisher","first-page":"5900","DOI":"10.1158\/1078-0432.CCR-05-0559","article-title":"Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma","volume":"11","author":"Yajima","year":"2005"},{"key":"b30-1080963","series-title":"Clin Cancer Res","doi-asserted-by":"publisher","first-page":"4160","DOI":"10.1158\/1078-0432.CCR-05-0120","article-title":"Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I\/II trial","volume":"11","author":"Yamanaka","year":"2005"},{"key":"b31-1080963","series-title":"Cancer Res","doi-asserted-by":"publisher","first-page":"4973","DOI":"10.1158\/0008-5472.CAN-03-3505","article-title":"Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma","volume":"64","author":"Yu","year":"2004"},{"key":"b32-1080963","series-title":"Br J Cancer","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1054\/bjoc.2000.1316","article-title":"A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse","volume":"83","author":"Yung","year":"2000"}],"container-title":["Journal of Neurosurgery"],"original-title":[],"link":[{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/108\/5\/article-p963.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/108\/5\/article-p963.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/108\/5\/article-p963.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T04:39:27Z","timestamp":1709959167000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/108\/5\/article-p963.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":32,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.3171\/jns\/2008\/108\/5\/0963","relation":{},"ISSN":["0022-3085","1933-0693"],"issn-type":[{"value":"0022-3085","type":"print"},{"value":"1933-0693","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5]]}}}